<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="973233cb-8cb1-4c1d-911e-649df1287843"/>
   <code code="34391-3" displayName="HUMAN PRESCRIPTION DRUG LABEL" codeSystem="2.16.840.1.113883.6.1"/>
   <title>
      <content styleCode="bold">These highlights do not include all the information needed to use METHYLPHENIDATE HYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for METHYLPHENIDATE HYDROCHLORIDE TABLETS.</content>
      <content styleCode="bold"> </content>
      <content styleCode="bold">
         <br/>
         <br/>METHYLPHENIDATE HYDROCHLORIDE tablets, for oral use, CII</content>
      <content styleCode="bold">
         <br/>Initial U.S. Approval: 1955</content>
   </title>
   <effectiveTime value="20250219"/>
   <setId root="c614cf55-b462-4f7e-b19c-6d22a47e509f"/>
   <versionNumber value="12"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="123797875" root="1.3.6.1.4.1.519.1"/>
            <name>Amneal Pharmaceuticals of New York LLC</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="123797875" root="1.3.6.1.4.1.519.1"/>
                        <name>Amneal Pharmaceuticals of New York, LLC</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" displayName="analysis" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0115-1800" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" displayName="analysis" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0115-1801" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" displayName="analysis" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0115-1802" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" displayName="manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0115-1800" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" displayName="manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0115-1801" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" displayName="manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0115-1802" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" displayName="pack" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0115-1800" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" displayName="pack" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0115-1801" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" displayName="pack" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0115-1802" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="808176705" root="1.3.6.1.4.1.519.1"/>
                        <name>Johnson Matthey Inc.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C82401" displayName="api manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0115-1800" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C82401" displayName="api manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0115-1801" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C82401" displayName="api manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0115-1802" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="0d9ae12a-6502-403c-b00d-b38ba6f22105"/>
               <code code="48780-1" displayName="SPL listing data elements section" codeSystem="2.16.840.1.113883.6.1"/>
               <effectiveTime value="20250219"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0115-1800" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>METHYLPHENIDATE HYDROCHLORIDE</name>
                        <formCode code="C42998" displayName="TABLET" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>METHYLPHENIDATE HYDROCHLORIDE</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="5"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="4B3SC438HI" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>METHYLPHENIDATE HYDROCHLORIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="207ZZ9QZ49" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>METHYLPHENIDATE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LACTOSE MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CELLULOSE, MICROCRYSTALLINE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="4ELV7Z65AP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>STEARIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="H77VEI93A8" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FD&amp;C YELLOW NO. 6</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="100"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="0115-1800-01" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43173" displayName="BOTTLE, PLASTIC" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20140407"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA091159" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" displayName="ANDA" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20140407"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <policy classCode="DEADrugSchedule">
                           <code code="C48675" displayName="CII" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </policy>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48331" displayName="orange" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV">
                              <originalText>Light Orange to Orange</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">cor;237</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48348" displayName="ROUND" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV">
                              <originalText>round</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="6" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" displayName="ORAL" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0115-1801" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>METHYLPHENIDATE HYDROCHLORIDE</name>
                        <formCode code="C42998" displayName="TABLET" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>METHYLPHENIDATE HYDROCHLORIDE</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="10"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="4B3SC438HI" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>METHYLPHENIDATE HYDROCHLORIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="207ZZ9QZ49" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>METHYLPHENIDATE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LACTOSE MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CELLULOSE, MICROCRYSTALLINE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="4ELV7Z65AP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>STEARIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="H77VEI93A8" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FD&amp;C YELLOW NO. 6</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="100"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="0115-1801-01" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43173" displayName="BOTTLE, PLASTIC" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20140407"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA091159" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" displayName="ANDA" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20140407"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <policy classCode="DEADrugSchedule">
                           <code code="C48675" displayName="CII" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </policy>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48331" displayName="orange" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV">
                              <originalText>Light Orange to Orange</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">cor;238</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="2" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48348" displayName="ROUND" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV">
                              <originalText>round</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="7" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" displayName="ORAL" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0115-1802" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>METHYLPHENIDATE HYDROCHLORIDE</name>
                        <formCode code="C42998" displayName="TABLET" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>METHYLPHENIDATE HYDROCHLORIDE</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="20"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="4B3SC438HI" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>METHYLPHENIDATE HYDROCHLORIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="207ZZ9QZ49" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>METHYLPHENIDATE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LACTOSE MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CELLULOSE, MICROCRYSTALLINE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="4ELV7Z65AP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>STEARIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="H77VEI93A8" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FD&amp;C YELLOW NO. 6</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="100"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="0115-1802-01" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43173" displayName="BOTTLE, PLASTIC" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20140407"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA091159" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" displayName="ANDA" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20140407"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <policy classCode="DEADrugSchedule">
                           <code code="C48675" displayName="CII" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </policy>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48331" displayName="orange" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV">
                              <originalText>Light Orange to Orange</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">cor;239</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="2" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48348" displayName="ROUND" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV">
                              <originalText>round</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="8" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" displayName="ORAL" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="LINK_8838fcf0-d459-4da9-bdce-4a47ec67cbbd">
               <id root="6a4fa942-4186-4af3-a175-01cd8eae87dc"/>
               <code code="34066-1" codeSystem="2.16.840.1.113883.6.1" displayName="BOXED WARNING SECTION"/>
               <title>WARNING: ABUSE, MISUSE, AND ADDICTION</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Methylphenidate hydrochloride has a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including </content>
                     <content styleCode="bold">methylphenidate hydrochloride, can result in overdose and death <content styleCode="italics">[see <linkHtml href="#www.splportal.comLINK_85cd87d0-dfcc-4ec2-a4a5-99b1cd9fe877">Overdosage (10)</linkHtml>]</content>, and this risk is increased with higher doses or unapproved methods of administration, such as snorting or injection.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold"> </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Before prescribing methylphenidate hydrochloride, assess each patient’s risk for abuse, misuse, and addiction. Educate patients and their families about these risks, proper storage of the drug, and proper disposal of any unused drug. Throughout methylphenidate hydrochloride treatment, reassess each patient’s risk of abuse, misuse, and addiction and frequently monitor for signs and symptoms of abuse, misuse, and addiction <content styleCode="italics">[see <linkHtml href="#www.splportal.comLINK_c96ab80b-f758-4ed6-bd73-5c111c1410ad">Warnings and Precautions (5.1)</linkHtml> </content>and <content styleCode="italics">
                           <linkHtml href="#www.splportal.comLINK_97dbb899-70dd-4de8-8619-a8e124f8ddee">Drug Abuse and Dependence (9.2)</linkHtml>]</content>.</content>
                  </paragraph>
               </text>
               <effectiveTime value="20250219"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>
                           <content styleCode="bold">WARNING: ABUSE, MISUSE, AND ADDICTION</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold"> </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">See full prescribing information for complete boxed warning.</content>
                           </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics"> </content>
                           </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">Methylphenidate hydrochloride </content>
                           <content styleCode="bold">has a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including </content>
                           <content styleCode="bold">methylphenidate hydrochloride</content>
                           <content styleCode="bold">, can result in overdose and death <linkHtml href="#LINK_c96ab80b-f758-4ed6-bd73-5c111c1410ad">(5.1</linkHtml>, <linkHtml href="#LINK_97dbb899-70dd-4de8-8619-a8e124f8ddee">9.2</linkHtml>, <linkHtml href="#LINK_85cd87d0-dfcc-4ec2-a4a5-99b1cd9fe877">10)</linkHtml>:</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold"> </content>
                        </paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="bold">Before prescribing </content>
                              <content styleCode="bold">methylphenidate hydrochloride</content>
                              <content styleCode="bold">, assess each patient’s risk for abuse, misuse, and addiction.</content>
                           </item>
                           <item>
                              <content styleCode="bold">Educate patients and their families about these risks, proper storage of the drug, and proper disposal of any unused drug.</content>
                           </item>
                           <item>
                              <content styleCode="bold"> </content>
                              <content styleCode="bold">Throughout treatment, reassess each patient’s risk and frequently monitor for signs and symptoms of abuse, misuse, and addiction.</content>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_cc924eef-bc6d-4841-a155-0ab69f4ca5e8">
               <id root="cfe02483-35e5-4748-8147-b188ccefa7de"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph> Methylphenidate hydrochloride tablets are indicated for the treatment of:</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Attention Deficit Hyperactivity Disorders (ADHD) in pediatric patients 6 years and older and adults</item>
                     <item>Narcolepsy</item>
                  </list>
               </text>
               <effectiveTime value="20250219"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Methylphenidate hydrochloride tablets are a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorders (ADHD) and Narcolepsy  (<linkHtml href="#LINK_48a0e91b-f312-4b7b-8793-a4243b21b18a">1</linkHtml>).</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_347c7ceb-a97c-4b66-8f7a-9c62367a60a6">
               <id root="cc345237-cb02-4955-8212-0fc60f1e070d"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <text/>
               <effectiveTime value="20250219"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Pediatric Patients 6 Years and Older: Start with 5 mg twice daily (before breakfast and lunch), titrating the dose weekly in 5 mg to 10 mg increments. Dosages above 60 mg/day are not recommended <linkHtml href="#LINK_0ed481ee-55e4-46d4-874c-d0857431ef84">(2.2)</linkHtml>.</item>
                           <item>Adults: Average daily dosage is 20 mg to 30 mg, administered 2 or 3 times daily, preferably 30 to 45 minutes before meals. Maximum total daily dosage is 60 mg <linkHtml href="#LINK_0ed481ee-55e4-46d4-874c-d0857431ef84">(2.2)</linkHtml>.</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_0729cfc3-2905-40fb-aa1b-d1f4ff53890b">
                     <id root="896046fa-a487-4a56-a5bb-d65a882ce021"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1 Pre-treatment
Screening</title>
                     <text>
                        <paragraph>Prior to treating patients with methylphenidate hydrochloride tablets, assess:</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>for the presence of cardiac disease (i.e., perform a careful history, family history of sudden death or ventricular arrhythmia, and physical exam) <content styleCode="italics">[see <linkHtml href="#www.splportal.comLINK_1f9a2b47-8373-4eb2-a622-cd2bb8edf511">Warnings and Precautions (5.2)</linkHtml>]</content>.</item>
                           <item>the family history and clinically evaluate patients for motor or verbal tics or Tourette’s syndrome before initiating methylphenidate hydrochloride tablets<content styleCode="italics"> [see <linkHtml href="#www.splportal.comLINK_f29a082f-65f3-4d24-a9b5-5051004f0f18">Warnings and Precautions (5.10)</linkHtml>]</content>.</item>
                        </list>
                     </text>
                     <effectiveTime value="20250219"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_0ed481ee-55e4-46d4-874c-d0857431ef84">
                     <id root="a9ae58e8-35de-47f5-b8e2-0b9bde65fdff"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2 General
Dosing Information</title>
                     <text>
                        <paragraph>
                           <content styleCode="italics">Pediatric Patients 6 years and Older: </content>Start with 5 mg orally twice daily (before breakfast and lunch). Increase dosage gradually, in increments of 5 mg to 10 mg weekly. Daily dosage above 60 mg is not recommended.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Adults: </content>Average dosage is 20 mg to 30 mg daily. Administer orally in divided doses 2 or 3 times daily, preferably 30 to 45 minutes before meals. Maximum total daily dosage is 60 mg. Patients who are unable to sleep if medication is taken late in the day should take the last dose before 6 p.m.</paragraph>
                     </text>
                     <effectiveTime value="20250219"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_c239ba1e-d800-430a-975d-d027118df478">
                     <id root="a6b9ca2e-306e-45e2-ad81-0a6ea0e0f4d4"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.3 Dosage Reduction and Discontinuation</title>
                     <text>
                        <paragraph>If paradoxical worsening of symptoms or other adverse reactions occur, reduce the dosage, or, if necessary, discontinue methylphenidate hydrochloride tablets. If improvement is not observed after appropriate dosage adjustment over a one-month period, the drug should be discontinued.</paragraph>
                     </text>
                     <effectiveTime value="20250219"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_e72ed83a-93a0-4692-bd2d-40ec3977f4a3">
               <id root="a2ba8828-f29a-45ef-a012-390ab67bb67a"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <list listType="unordered" styleCode="Disc">
                     <item>Methylphenidate hydrochloride tablets USP, 5 mg are light orange to orange, round compressed tablets, debossed <content styleCode="bold">cor </content>on one side and <content styleCode="bold">237 </content>on the other side.</item>
                     <item>Methylphenidate hydrochloride tablets USP, 10 mg are light orange to orange, round compressed tablets, debossed <content styleCode="bold">cor </content>above <content styleCode="bold">bisect </content>and <content styleCode="bold">238 </content>below the bisect on one side and plain on the other side.</item>
                     <item>Methylphenidate hydrochloride tablets USP, 20 mg are light orange to orange, round compressed tablets, debossed <content styleCode="bold">cor </content>over <content styleCode="bold">239 </content>on one side and <content styleCode="bold">bisect </content>on the other side.</item>
                  </list>
               </text>
               <effectiveTime value="20250219"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Tablets: 5 mg, 10 mg, 20 mg (<linkHtml href="#LINK_ed9cc327-a9b2-497e-8154-bd9219fd4770">3</linkHtml>).</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_0c31c45d-6947-421e-877b-0c482d1351ba">
               <id root="0751fb5c-85b6-4516-b5e5-3915069d6240"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <list listType="unordered" styleCode="Disc">
                     <item>Hypersensitivity to methylphenidate or other components of methylphenidate hydrochloride tablets. Hypersensitivity reactions, such as angioedema and anaphylactic reactions, have been reported in patients treated with methylphenidate <content styleCode="italics">[see <linkHtml href="#LINK_47191684-9b2a-4833-b9c3-fea375dd1862">Adverse Reactions (6)</linkHtml>].</content>
                     </item>
                     <item>Concomitant treatment with monoamine oxidase inhibitors (MAOIs), or within 14 days following discontinuation of treatment with an MAOI, because of the risk of hypertensive crises <content styleCode="italics">[see <linkHtml href="#LINK_70723a2e-630d-4cb7-9d6c-c6ed5b7ece37">Drug Interactions (7.1)</linkHtml>].</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20250219"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Known hypersensitivity to methylphenidate or other product components of methylphenidate hydrochloride tablets (<linkHtml href="#LINK_7600ad47-5a2d-4055-b6a8-9334addd62c5">4</linkHtml>).</item>
                           <item>Concurrent treatment with a monoamine oxidase inhibitor (MAOI), or use of an MAOI within the preceding 14 days (<linkHtml href="#LINK_7600ad47-5a2d-4055-b6a8-9334addd62c5">4</linkHtml>).</item>
                        </list>
                        <paragraph>  <br/>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_8fc8abc2-3ffc-4487-b7f2-eec01933bdcf">
               <id root="4f605b71-825a-4822-a1b8-80b7afe2d83e"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <text/>
               <effectiveTime value="20250219"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="italics">Risks to Patients with Serious Cardiac Disease:</content> Avoid use in patients with known structural cardiac abnormalities, cardiomyopathy, serious cardiac arrhythmias, coronary artery disease, or other serious cardiac disease <linkHtml href="#LINK_1f9a2b47-8373-4eb2-a622-cd2bb8edf511">(5.2)</linkHtml>.</item>
                           <item>
                              <content styleCode="italics">Increased Blood Pressure and Heart Rate:</content> Monitor blood pressure and pulse <linkHtml href="#LINK_ee01e211-af26-45f2-b0b3-029dced0f0bb">(5.3)</linkHtml>.</item>
                           <item>
                              <content styleCode="italics">Psychiatric Adverse Reactions:</content> Prior to initiating methylphenidate hydrochloride, screen patients for risk factors for developing a manic episode. If new psychotic or manic symptoms occur, consider discontinuing methylphenidate hydrochloride <linkHtml href="#LINK_59e56115-b452-4512-ae37-4f958ebb7f0a">(5.4)</linkHtml>.</item>
                           <item>
                              <content styleCode="italics">Priapism:</content> If abnormally sustained or frequent and painful erections occur, patients should seek immediate medical attention <linkHtml href="#LINK_56c5a188-e205-4c08-bbf4-37ac98ad36d1">(5.5)</linkHtml>.</item>
                           <item>
                              <content styleCode="italics">Peripheral Vasculopathy, Including Raynaud’s Phenomenon:</content> Careful observation for digital changes is necessary during methylphenidate hydrochloride treatment. Further clinical evaluation (e.g., rheumatology referral) may be appropriate for patients who develop signs or symptoms of peripheral vasculopathy <linkHtml href="#LINK_28a40a99-6c79-467f-8155-8d573f38d88e">(5.6)</linkHtml>.</item>
                           <item>
                              <content styleCode="italics">Long-Term Suppression of Growth in Pediatric Patients:</content> Closely monitor growth (height and weight) in pediatric patients. Pediatric patients not growing or gaining height or weight as expected may need to have their treatment interrupted <linkHtml href="#LINK_90c6eac8-4d1f-4927-9954-5e8dcb549a15">(5.7)</linkHtml>.</item>
                           <item>
                              <content styleCode="italics">Acute Angle Closure Glaucoma:</content> Methylphenidate hydrochloride-treated patients considered at risk for acute angle closure glaucoma (e.g., patients with significant hyperopia) should be evaluated by an ophthalmologist <linkHtml href="#LINK_f509a582-802f-4f86-8512-26643d3fcfc3">(5.8)</linkHtml>.</item>
                           <item>
                              <content styleCode="italics">Increased Intraocular Pressure (IOP) and Glaucoma:</content> Prescribe methylphenidate hydrochloride to patients with open-angle glaucoma or abnormally increased IOP only if the benefit of treatment is considered to outweigh the risk. Closely monitor patients with a history of increased IOP or open angle glaucoma <linkHtml href="#LINK_e47d8db2-1651-4114-836e-980b11f1eda3">(5.9)</linkHtml>.</item>
                           <item>
                              <content styleCode="italics">Motor and Verbal Tics, and Worsening of Tourette’s Syndrome:</content> Before initiating methylphenidate hydrochloride, assess the family history and clinically evaluate patients for tics or Tourette’s syndrome. Regularly monitor patients for the emergence or worsening of tics or Tourette’s syndrome. Discontinue treatment if clinically appropriate <linkHtml href="#LINK_f29a082f-65f3-4d24-a9b5-5051004f0f18">(5.10)</linkHtml>.</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_c96ab80b-f758-4ed6-bd73-5c111c1410ad">
                     <id root="1c18a0b7-67d9-45d8-8731-5831a52b7fd3"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Abuse, Misuse, and Addiction</title>
                     <text>
                        <paragraph>Methylphenidate hydrochloride have a high potential for abuse and misuse. The use of methylphenidate hydrochloride exposes individuals to the risks of abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Methylphenidate hydrochloride can be diverted for non-medical use into illicit channels or distribution <content styleCode="italics">[see <linkHtml href="#www.splportal.comLINK_97dbb899-70dd-4de8-8619-a8e124f8ddee">Drug Abuse and Dependence (9.2)</linkHtml>]</content>. Misuse and abuse of CNS stimulants, including methylphenidate hydrochloride, can result in overdose and death <content styleCode="italics">[see <linkHtml href="#www.splportal.comLINK_85cd87d0-dfcc-4ec2-a4a5-99b1cd9fe877">Overdosage (10)</linkHtml>]</content>, and this risk is increased with higher doses or unapproved methods of administration, such as snorting or injection.</paragraph>
                        <paragraph>Before prescribing methylphenidate hydrochloride, assess each patient’s risk for abuse, misuse, and addiction. Educate patients and their families about these risks and proper disposal of any unused drug. Advise patients to store methylphenidate hydrochloride in a safe place, preferably locked, and instruct patients to not give methylphenidate hydrochloride to anyone else. Throughout methylphenidate hydrochloride treatment, reassess each patient’s risk of abuse, misuse, and addiction and frequently monitor for signs and symptoms of abuse, misuse, and addiction.</paragraph>
                     </text>
                     <effectiveTime value="20250219"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_1f9a2b47-8373-4eb2-a622-cd2bb8edf511">
                     <id root="4f07b635-f153-4262-920b-3d07b15eed3e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 Risks to Patients with Serious Cardiac Disease</title>
                     <text>
                        <paragraph>Sudden death has been reported in patients with structural cardiac abnormalities or other serious cardiac disease who are treated with CNS stimulants at the recommended ADHD dosage. </paragraph>
                        <paragraph>Avoid methylphenidate hydrochloride use in patients with known serious structural cardiac abnormalities, cardiomyopathy, serious cardiac arrhythmia, coronary artery disease, or other serious cardiac disease. </paragraph>
                     </text>
                     <effectiveTime value="20250219"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_ee01e211-af26-45f2-b0b3-029dced0f0bb">
                     <id root="89da24c5-6720-48dc-8e5b-475c8e9028f3"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3 Increased Blood Pressure and Heart Rate</title>
                     <text>
                        <paragraph>CNS stimulants cause an increase in blood pressure (mean increase approximately 2 mmHg to 4 mmHg) and heart rate (mean increase approximately 3 bpm to 6 bpm). Some patients may have larger increases.</paragraph>
                        <paragraph>Monitor all methylphenidate hydrochloride-treated patients for hypertension and tachycardia.</paragraph>
                     </text>
                     <effectiveTime value="20250219"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_59e56115-b452-4512-ae37-4f958ebb7f0a">
                     <id root="04693e13-8cd9-40b9-8860-4b920717fca4"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4 Psychiatric
Adverse Reactions</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Exacerbation of Pre-existing Psychosis</content>
                        </paragraph>
                        <paragraph>CNS stimulants may exacerbate symptoms of behavior disturbance and thought disorder in patients with a pre-existing psychotic disorder.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Induction of a Manic Episode in Patients with Bipolar Disorder</content>
                        </paragraph>
                        <paragraph>CNS stimulants may induce a manic or mixed mood episode in patients. Prior to initiating methylphenidate hydrochloride treatment, screen patients for risk factors for developing a manic episode (e.g., comorbid or history of depressive symptoms or a family history of suicide, bipolar disorder, or depression).</paragraph>
                        <paragraph>
                           <content styleCode="underline">New Psychotic or Manic Symptoms</content>
                        </paragraph>
                        <paragraph>CNS stimulants, at the recommended dosage, may cause psychotic or manic symptoms (e.g., hallucinations, delusional thinking, or mania) in patients without a prior history of psychotic illness or mania. In a pooled analysis of multiple short-term, placebo-controlled studies of CNS stimulants, psychotic or manic symptoms occurred in approximately 0.1% of CNS stimulant-treated patients, compared to 0% of placebo-treated patients. If such symptoms occur, consider discontinuing methylphenidate hydrochloride.</paragraph>
                     </text>
                     <effectiveTime value="20250219"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_56c5a188-e205-4c08-bbf4-37ac98ad36d1">
                     <id root="52d418eb-6646-447d-ad33-cc2787eb2f49"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.5 Priapism</title>
                     <text>
                        <paragraph>Prolonged and painful erections, sometimes requiring surgical intervention, have been reported with methylphenidate use in both adult and pediatric male patients. Although priapism was not reported with methylphenidate initiation, it developed after some time on methylphenidate, often subsequent to an increase in dosage. Priapism has also occurred during methylphenidate withdrawal (drug holidays or during discontinuation). </paragraph>
                        <paragraph>Methylphenidate hydrochloride-treated patients who develop abnormally sustained or frequent and painful erections should seek immediate medical attention.</paragraph>
                     </text>
                     <effectiveTime value="20250219"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_28a40a99-6c79-467f-8155-8d573f38d88e">
                     <id root="21f6260f-3890-44e4-af56-cad9f8033f91"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.6 Peripheral
Vasculopathy, Including Raynaud’s Phenomenon</title>
                     <text>
                        <paragraph>CNS stimulants, including methylphenidate hydrochloride, used to treat ADHD are associated with peripheral vasculopathy, including Raynaud’s phenomenon. Signs and symptoms are usually intermittent and mild; however, sequelae have included digital ulceration and/or soft tissue breakdown. Effects of peripheral vasculopathy, including Raynaud’s phenomenon, were observed in post-marketing reports and at the therapeutic dosage of CNS stimulants in all age groups throughout the course of treatment. Signs and symptoms generally improved after dosage reduction or discontinuation of the CNS stimulant. </paragraph>
                        <paragraph>Careful observation for digital changes is necessary during methylphenidate hydrochloride treatment. Further clinical evaluation (e.g., rheumatology referral) may be appropriate for methylphenidate hydrochloride-treated patients who develop signs or symptoms of peripheral vasculopathy.</paragraph>
                     </text>
                     <effectiveTime value="20250219"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_90c6eac8-4d1f-4927-9954-5e8dcb549a15">
                     <id root="61ae43b1-ecfc-47e7-bf50-420dd1c38315"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.7 Long-Term Suppression of Growth in Pediatric Patients</title>
                     <text>
                        <paragraph>CNS stimulants have been associated with weight loss and slowing of growth rate in pediatric patients.</paragraph>
                        <paragraph>Careful follow-up of weight and height in pediatric patients ages 7 to 10 years who were randomized to either methylphenidate or non-medication treatment groups over 14 months, as well as in naturalistic subgroups of newly methylphenidate-treated and non-medication treated patients over 36 months (to the ages of 10 to 13 years), suggests that pediatric patients who received methylphenidate for 7 days per week throughout the year had a temporary slowing in growth rate (on average, a total of about 2 cm less growth in height and 2.7 kg less growth in weight over 3 years), without evidence of growth rebound during this development period.</paragraph>
                        <paragraph>Closely monitor growth (weight and height) in methylphenidate hydrochloride-treated pediatric patients. Pediatric patients who are not growing or gaining height or weight as expected may need to have their treatment interrupted.</paragraph>
                     </text>
                     <effectiveTime value="20250219"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_f509a582-802f-4f86-8512-26643d3fcfc3">
                     <id root="ac3327ee-b465-4c01-abfa-a239b1d295c5"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.8 Acute Angle Closure Glaucoma</title>
                     <text>
                        <paragraph>There have been reports of angle closure glaucoma associated with methylphenidate treatment.</paragraph>
                        <paragraph>Although the mechanism is not clear, methylphenidate hydrochloride-treated patients considered at risk for acute angle closure glaucoma (e.g., patients with significant hyperopia) should be evaluated by an ophthalmologist.</paragraph>
                        <paragraph>
                           <br/>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250219"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_e47d8db2-1651-4114-836e-980b11f1eda3">
                     <id root="c85f94de-b006-4e7d-a67e-6132dbeb2485"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.9 Increased Intraocular Pressure and Glaucoma</title>
                     <text>
                        <paragraph>There have been reports of an elevation of intraocular pressure (IOP) associated with methylphenidate treatment <content styleCode="italics">[see <linkHtml href="#LINK_47191684-9b2a-4833-b9c3-fea375dd1862">Adverse Reactions (6)</linkHtml>]</content>.</paragraph>
                        <paragraph>Prescribe methylphenidate hydrochloride to patients with open-angle glaucoma or abnormally increased IOP only if the benefit of treatment is considered to outweigh the risk. Closely monitor methylphenidate hydrochloride-treated patients with a history of abnormally increased IOP or open angle glaucoma.</paragraph>
                     </text>
                     <effectiveTime value="20250219"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_f29a082f-65f3-4d24-a9b5-5051004f0f18">
                     <id root="449ec188-6f0c-4615-afdd-6be329d27e55"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.10 Motor and Verbal Tics, and Worsening of Tourette’s Syndrome</title>
                     <text>
                        <paragraph>CNS stimulants, including methylphenidate, have been associated with the onset or exacerbation of motor and verbal tics. Worsening of Tourette’s syndrome has also been reported <content styleCode="italics">[see <linkHtml href="#LINK_47191684-9b2a-4833-b9c3-fea375dd1862">Adverse Reactions (6)</linkHtml>]</content>.</paragraph>
                        <paragraph>Before initiating methylphenidate hydrochloride, assess the family history and clinically evaluate patients for tics or Tourette’s syndrome. Regularly monitor methylphenidate hydrochloride-treated patients for the emergence or worsening of tics or Tourette’s syndrome, and discontinue treatment if clinically appropriate.</paragraph>
                     </text>
                     <effectiveTime value="20250219"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_47191684-9b2a-4833-b9c3-fea375dd1862">
               <id root="f81a3250-f9bb-4f01-af42-dd67b575c20b"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following are discussed in more detail in other sections of the labeling:</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Abuse, Misuse, and Addiction <content styleCode="italics">[see <linkHtml href="#www.splportal.comLINK_bb7ceb11-60f8-401d-96f1-e2c3a6687b98">Boxed Warning</linkHtml>, <linkHtml href="#LINK_c96ab80b-f758-4ed6-bd73-5c111c1410ad">Warnings and Precautions (5.1)</linkHtml>, <linkHtml href="#LINK_97dbb899-70dd-4de8-8619-a8e124f8ddee">Drug Abuse and Dependence (9.2</linkHtml>, <linkHtml href="#LINK_5cd2698b-cc83-4cd9-8f9a-5139ddc4385d">9.3)</linkHtml>]</content>
                     </item>
                     <item>Known hypersensitivity to methylphenidate or other ingredients of methylphenidate hydrochloride tablets <content styleCode="italics">[see <linkHtml href="#LINK_0c31c45d-6947-421e-877b-0c482d1351ba">Contraindications (4)</linkHtml>]</content>
                     </item>
                     <item>Hypertensive crisis with Concomitant Use of Monoamine Oxidase Inhibitors <content styleCode="italics">[see <linkHtml href="#LINK_0c31c45d-6947-421e-877b-0c482d1351ba">Contraindications (4)</linkHtml>, <linkHtml href="#LINK_70723a2e-630d-4cb7-9d6c-c6ed5b7ece37">Drug Interactions (7.1)</linkHtml>]</content>
                     </item>
                     <item>Risks to Patients with Serious Cardiac Disease <content styleCode="italics">[see <linkHtml href="#LINK_1f9a2b47-8373-4eb2-a622-cd2bb8edf511">Warnings and Precautions (5.2)</linkHtml>]</content>
                     </item>
                     <item>Increased Blood Pressure and Heart Rate <content styleCode="italics">[see <linkHtml href="#LINK_ee01e211-af26-45f2-b0b3-029dced0f0bb">Warnings and Precautions (5.3)</linkHtml>]</content>
                     </item>
                     <item>Psychiatric Adverse Reactions <content styleCode="italics">[see <linkHtml href="#LINK_59e56115-b452-4512-ae37-4f958ebb7f0a">Warnings and Precautions (5.4)</linkHtml>]</content>
                     </item>
                     <item>Priapism <content styleCode="italics">[see <linkHtml href="#LINK_56c5a188-e205-4c08-bbf4-37ac98ad36d1">Warnings and Precautions (5.5)</linkHtml>]</content>
                     </item>
                     <item>Peripheral Vasculopathy, including Raynaud’s Phenomenon <content styleCode="italics">[see <linkHtml href="#LINK_28a40a99-6c79-467f-8155-8d573f38d88e">Warnings and Precautions (5.6)</linkHtml>]</content>
                     </item>
                     <item>Long-term Suppression of Growth in Pediatric Patients <content styleCode="italics">[see <linkHtml href="#LINK_90c6eac8-4d1f-4927-9954-5e8dcb549a15">Warnings and Precautions (5.7)</linkHtml>]</content>
                     </item>
                     <item>Acute Angle Closure Glaucoma <content styleCode="italics">[see <linkHtml href="#LINK_f509a582-802f-4f86-8512-26643d3fcfc3">Warnings and Precautions (5.8)</linkHtml>]</content>
                     </item>
                     <item>Increased Intraocular Pressure and Glaucoma <content styleCode="italics">[see <linkHtml href="#LINK_e47d8db2-1651-4114-836e-980b11f1eda3">Warnings and Precautions (5.9)</linkHtml>]</content>
                     </item>
                     <item>Motor and Verbal Tics, and Worsening of Tourette’s Syndrome <content styleCode="italics">[see <linkHtml href="#LINK_f29a082f-65f3-4d24-a9b5-5051004f0f18">Warnings and Precautions (5.10)</linkHtml>]</content>
                     </item>
                  </list>
                  <paragraph>The following adverse reactions associated with the use of methylphenidate hydrochloride tablets and other methylphenidate products were identified in clinical trials, spontaneous reports, and literature. Because these reactions were reported voluntarily from a population of uncertain size, it is not always possible to estimate their frequency reliably or to establish a causal relationship to drug exposure.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Adverse Reactions Reported with </content>
                     <content styleCode="underline">Methylphenidate Hydrochloride </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="italics">Infections and Infestations: </content>nasopharyngitis</paragraph>
                  <paragraph>
                     <content styleCode="italics">Blood and the Lymphatic System Disorders: </content>leukopenia, thrombocytopenia, anemia</paragraph>
                  <paragraph>
                     <content styleCode="italics">Immune System Disorders: </content>hypersensitivity reactions, including angioedema, and anaphylaxis</paragraph>
                  <paragraph>
                     <content styleCode="italics">Metabolism and Nutrition Disorders: </content>decreased appetite, reduced weight gain, and suppression of growth during prolonged use in pediatric patients</paragraph>
                  <paragraph>
                     <content styleCode="italics">Psychiatric Disorders: </content>insomnia, anxiety, restlessness, agitation, psychosis (sometimes with visual and tactile hallucinations), depressed mood, depression</paragraph>
                  <paragraph>
                     <content styleCode="italics">Nervous System Disorders: </content>headache, dizziness, tremor, dyskinesia, including choreoatheetoid movements, drowsiness, convulsions, cerebrovascular disorders (including vasculitis, cerebral hemorrhages and cerebrovascular accidents), serotonin syndrome in combination with serotonergic drugs</paragraph>
                  <paragraph>
                     <content styleCode="italics">Eye Disorders: </content>blurred vision, difficulties in visual accommodation</paragraph>
                  <paragraph>
                     <content styleCode="italics">Cardiac Disorders: </content>tachycardia, palpitations, increased blood pressure, arrhythmias, angina pectoris</paragraph>
                  <paragraph>
                     <content styleCode="italics">Respiratory, Thoracic, and Mediastinal Disorders: </content>cough</paragraph>
                  <paragraph>
                     <content styleCode="italics">Gastrointestinal Disorders: </content>dry mouth, nausea, vomiting, abdominal pain, dyspepsia</paragraph>
                  <paragraph>
                     <content styleCode="italics">Hepatobiliary Disorders: </content>abnormal liver function, ranging from transaminase elevation to severe hepatic injury</paragraph>
                  <paragraph>
                     <content styleCode="italics">Skin and Subcutaneous Tissue Disorders: </content>hyperhidrosis, pruritus, urticaria, exfoliative dermatitis, scalp hair loss, erythema multiforme rash, thrombocytopenic purpura</paragraph>
                  <paragraph>
                     <content styleCode="italics">Musculoskeletal and Connective Tissue Disorders: </content>arthralgia, muscle cramps, rhabdomyolysis, trismus</paragraph>
                  <paragraph>
                     <content styleCode="italics">Investigations: </content>weight loss (adult ADHD patients)</paragraph>
                  <paragraph>
                     <content styleCode="italics">Vascular Disorders:</content> peripheral coldness, Raynaud's phenomenon</paragraph>
                  <paragraph>
                     <content styleCode="underline">Additional Adverse Reactions Reported with Other Methylphenidate-Containing Products</content>
                  </paragraph>
                  <paragraph>The list below shows adverse reactions not listed for methylphenidate hydrochloride tablets, that have been reported with other methylphenidate-containing products.</paragraph>
                  <paragraph>
                     <content styleCode="italics">Blood and Lymphatic Disorders: </content>pancytopenia</paragraph>
                  <paragraph>
                     <content styleCode="italics">Immune System Disorders: </content>hypersensitivity reactions, such as auricular swelling, bullous conditions, eruptions, exanthemas</paragraph>
                  <paragraph>
                     <content styleCode="italics">Psychiatric Disorders: </content>affect lability, mania, disorientation, and libido changes</paragraph>
                  <paragraph>
                     <content styleCode="italics">Nervous System Disorders: </content>migraine, motor and verbal tics</paragraph>
                  <paragraph>
                     <content styleCode="italics">Eye Disorders: </content>diplopia, increased intraocular pressure, mydriasis</paragraph>
                  <paragraph>
                     <content styleCode="italics">Cardiac Disorders: </content>sudden cardiac death, myocardial infarction, bradycardia, extrasystole</paragraph>
                  <paragraph>
                     <content styleCode="italics">Respiratory, Thoracic, and Mediastinal Disorders: </content>pharyngolaryngeal pain, dyspnea</paragraph>
                  <paragraph>
                     <content styleCode="italics">Gastrointestinal Disorders: </content>diarrhea, constipation</paragraph>
                  <paragraph>
                     <content styleCode="italics">Skin and Subcutaneous Tissue Disorders: </content>angioneurotic edema, erythema, fixed drug eruption</paragraph>
                  <paragraph>
                     <content styleCode="italics">Musculoskeletal, Connective Tissue, and Bone Disorders: </content>myalgia, muscle twitching</paragraph>
                  <paragraph>
                     <content styleCode="italics">Renal and Urinary Disorders: </content>hematuria</paragraph>
                  <paragraph>
                     <content styleCode="italics">Reproductive System and Breast Disorders: </content>gynecomastia</paragraph>
                  <paragraph>
                     <content styleCode="italics">General Disorders: </content>fatigue, hyperpyrexia</paragraph>
                  <paragraph>
                     <content styleCode="italics">Urogenital Disorders:</content> priapism</paragraph>
               </text>
               <effectiveTime value="20250219"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Common adverse reactions: tachycardia, palpitations, headache, insomnia, anxiety, hyperhidrosis, weight loss, decreased appetite, dry mouth, nausea, and abdominal pain (<linkHtml href="#LINK_9440e503-baf7-441c-991f-439bc85d32c3">6</linkHtml>).</paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Amneal Pharmaceuticals at 1-877-835-5472 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_1a996bf6-82fe-47de-9173-413e4bfa8613">
               <id root="f6819945-f0a4-4b0d-a305-2bb81d668998"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <text/>
               <effectiveTime value="20250219"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="italics">Antihypertensive Drugs:</content> Monitor blood pressure. Adjust dosage of antihypertensive drug as needed (<linkHtml href="#LINK_502b69ea-bc62-44f2-99bf-3b1e2befd8e4">7.1</linkHtml>).</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_70723a2e-630d-4cb7-9d6c-c6ed5b7ece37">
                     <id root="05cec12f-136a-44a8-a2fe-9f0452ea2d88"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.1 Clinically
Important Drug Interactions with Methylphenidate
Hydrochloride</title>
                     <text>
                        <paragraph>Table 1 presents clinically important drug interactions with methylphenidate hydrochloride.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Table 1: Clinically Important Drug Interactions with Methylphenidate Hydrochloride</content>
                        </paragraph>
                        <table width="100%" cellspacing="0" cellpadding="0" border="1">
                           <col width="17pt"/>
                           <col/>
                           <tbody>
                              <tr>
                                 <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Monoamine Oxidase Inhibitors (MAOI)</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="italics">Clinical Impact</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Concomitant use of MAOIs and CNS stimulants, including methylphenidate hydrochloride can cause hypertensive crisis. Potential outcomes include death, stroke, myocardial infarction, aortic dissection, ophthalmological complications, eclampsia, pulmonary edema, and renal failure <content styleCode="italics">[see <linkHtml href="#LINK_0c31c45d-6947-421e-877b-0c482d1351ba">Contraindications (4)</linkHtml>]</content>.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="italics">Intervention</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Concomitant use of methylphenidate hydrochloride with MAOIs or within 14 days after discontinuing MAOI treatment is contraindicated.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Antihypertensive Drugs</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="italics">Clinical Impact</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Methylphenidate hydrochloride may decrease the effectiveness of drugs used to treat hypertension <content styleCode="italics">[see <linkHtml href="#LINK_ee01e211-af26-45f2-b0b3-029dced0f0bb">Warnings and Precautions (5.3)</linkHtml>]</content>.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="italics">Intervention</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Monitor blood pressure and adjust the dosage of the antihypertensive drug as needed.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Halogenated Anesthetics</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="italics">Clinical Impact</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Concomitant use of halogenated anesthetics and methylphenidate hydrochloride may increase the risk of sudden blood pressure and heart rate increase during surgery.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="italics">Intervention</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Avoid use of methylphenidate hydrochloride in patients being treated with anesthetics on the day of surgery.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="bold">Risperidone</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> 
            <paragraph>
                                       <content styleCode="italics">Clinical Impact</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Combined use of methylphenidate with risperidone when there is a change, whether an increase or decrease, in dosage of either or both medications, may increase the risk of extrapyramidal symptoms (EPS)</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> 
            <paragraph>
                                       <content styleCode="italics">Intervention</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Monitor for signs of EPS</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20250219"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_89c8ea8e-bca3-4887-b737-f22761ca9b80">
               <id root="da95c2f1-bd42-4418-9236-de5bf2bdbc59"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <text/>
               <effectiveTime value="20250219"/>
               <component>
                  <section ID="LINK_a5cc5456-2fc5-4095-b41b-6009cc71135a">
                     <id root="d557ff50-548e-415e-bf10-4306f6cf4688"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Pregnancy Exposure Registry </content>
                        </paragraph>
                        <paragraph>There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to ADHD medications, including methylphenidate hydrochloride, during pregnancy. Healthcare providers are encouraged to register patients by calling the National Pregnancy Registry for ADHD Medications at 1-866-961-2388 or visiting <linkHtml href="https://womensmentalhealth.org/adhd-medications/">https://womensmentalhealth.org/adhd-medications/</linkHtml>.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Risk Summary </content>
                        </paragraph>
                        <paragraph>Published studies and post-marketing reports on methylphenidate use during pregnancy have not identified a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. There may be risks to the fetus associated with the use of CNS stimulants use during pregnancy <content styleCode="italics">(see <linkHtml href="#LINK_0678038c-f854-448e-8947-78842ce43fd8">Clinical Considerations</linkHtml>)</content>. </paragraph>
                        <paragraph>No effects on morphological development were observed in embryo-fetal development studies with oral administration of methylphenidate to pregnant rats and rabbits during organogenesis at doses up to 10 and 15 times, respectively, the maximum recommended human dose (MRHD) of 60 mg/day given to adolescents on a mg/m<sup>2</sup> basis. However, spina bifida was observed in rabbits at a dose 52 times the MRHD given to adolescents. A decrease in pup body weight was observed in a pre- and post-natal development study with oral administration of methylphenidate to rats throughout pregnancy and lactation at doses 6 times the MRHD given to adolescents <content styleCode="italics">(see <linkHtml href="#LINK_907a6ecb-031d-4ad0-9930-e4177cc0a61a">Data</linkHtml>)</content>. </paragraph>
                        <paragraph>The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. </paragraph>
                     </text>
                     <effectiveTime value="20250219"/>
                     <component>
                        <section ID="LINK_0678038c-f854-448e-8947-78842ce43fd8">
                           <id root="bf23e7f4-99b0-4e91-a4bd-25f5b5cceb63"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="underline">Clinical Considerations</content>
                           </title>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Fetal/Neonatal Adverse Reactions</content>
                              </paragraph>
                              <paragraph>CNS stimulants, such as methylphenidate hydrochloride, can cause vasoconstriction and thereby decrease placental perfusion. No fetal and/or neonatal adverse reactions have been reported with the use of therapeutic doses of methylphenidate during pregnancy; however, premature delivery and low birth weight infants have been reported in amphetamine-dependent mothers.</paragraph>
                           </text>
                           <effectiveTime value="20250219"/>
                        </section>
                     </component>
                     <component>
                        <section ID="LINK_907a6ecb-031d-4ad0-9930-e4177cc0a61a">
                           <id root="899ef4c8-3cf6-401c-a148-edb6d78aa093"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="underline">Data</content>
                           </title>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Animal Data</content>
                              </paragraph>
                              <paragraph>In embryo-fetal development studies conducted in rats and rabbits, methylphenidate was administered orally at doses of up to 75 and 200 mg/kg/day, respectively, during the period of organogenesis. Malformations (increased incidence of fetal spina bifida) were observed in rabbits at the highest dose, which is approximately 52 times the MRHD of 60 mg/day given to adolescents on a mg/m<sup>2</sup> basis. The no effect level for embryo-fetal development in rabbits was 60 mg/kg/day (15 times the MRHD given to adolescents on a mg/m<sup>2</sup> basis). There was no evidence of morphological development effects in rats, although increased incidences of fetal skeletal variations were seen at the highest dose level (10 times the MRHD of 60 mg/day given to adolescents on a mg/m<sup>2</sup> basis), which was also maternally toxic. The no effect level for embryo-fetal development in rats was 25 mg/kg/day (3 times the MRHD on a mg/m<sup>2</sup> basis). When methylphenidate was administered to rats throughout pregnancy and lactation at doses of up to 45 mg/kg/day, offspring body weight gain was decreased at the highest dose (6 times the MRHD of 60 mg/day given to adolescents on a mg/m<sup>2</sup> basis), but no other effects on postnatal development were observed. The no effect level for pre- and postnatal development in rats was 15 mg/kg/day (approximately 2 times the MRHD given to adolescents on a mg/m<sup>2</sup> basis).</paragraph>
                           </text>
                           <effectiveTime value="20250219"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="LINK_23e3cdb4-41f6-4ac4-b923-f629459b0d16">
                     <id root="fd2e4e1e-9361-4592-90ab-e8fc4ed65c9d"/>
                     <code code="34080-2" codeSystem="2.16.840.1.113883.6.1" displayName="NURSING MOTHERS SECTION"/>
                     <title>8.2 Lactation</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary </content>
                        </paragraph>
                        <paragraph>Limited published literature, based on milk sampling from seven mothers, reports that methylphenidate is present in human milk, which resulted in infant doses of 0.16% to 0.7% of the maternal weight-adjusted dosage and a milk/plasma ratio ranging between 1.1 and 2.7. There are no reports of adverse effects on the breastfed infant and no effects on milk production. Long-term neurodevelopmental effects on infants from stimulant exposure are unknown. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for methylphenidate hydrochloride and any potential adverse effects on the breastfed infant from methylphenidate hydrochloride or from the underlying maternal condition. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Clinical Considerations </content>
                        </paragraph>
                        <paragraph>Monitor breastfeeding infants for adverse reactions, such as agitation, insomnia, anorexia, and reduced weight gain.</paragraph>
                     </text>
                     <effectiveTime value="20250219"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_c4fa8285-ae1e-427b-9edf-63b2700eba2e">
                     <id root="0f24405d-58c6-4b8b-b638-888019f973f9"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>The safety and effectiveness of methylphenidate hydrochloride for the treatment of ADHD have been established in pediatric patients aged 6 to 17 years.</paragraph>
                        <paragraph>The safety and effectiveness of methylphenidate hydrochloride in pediatric patients aged less than 6 years have not been established.</paragraph>
                        <paragraph>The long-term efficacy of methylphenidate in pediatric patients has not been established.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Long-Term Suppression of Growth</content>
                        </paragraph>
                        <paragraph>Growth should be monitored during treatment with stimulants, including methylphenidate hydrochloride. Pediatric patients who are not growing or gaining weight as expected may need to have their treatment interrupted <content styleCode="italics">[see <linkHtml href="#LINK_90c6eac8-4d1f-4927-9954-5e8dcb549a15">Warnings and Precautions (5.7)</linkHtml>]</content>.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Juvenile Animal Toxicity Data</content>
                        </paragraph>
                        <paragraph>Rats treated with methylphenidate early in the postnatal period through sexual maturation demonstrated a decrease in spontaneous locomotor activity in adulthood. A deficit in acquisition of a specific learning task was observed in females only. The doses at which these findings were observed are at least 4 times the MRHD of 60 mg/day given to children on a mg/m<sup>2</sup> basis.</paragraph>
                        <paragraph>In a study conducted in young rats, methylphenidate was administered orally at doses of up to 100 mg/kg/day for 9 weeks, starting early in the postnatal period (postnatal Day 7) and continuing through sexual maturity (postnatal Week 10). When these animals were tested as adults (postnatal Weeks 13 to 14), decreased spontaneous locomotor activity was observed in males and females previously treated with 50 mg/kg/day (approximately 4 times the MRHD of 60 mg/day given to children on a mg/m<sup>2</sup> basis) or greater, and a deficit in the acquisition of a specific learning task was seen in females exposed to the highest dose (8 times the MRHD given to children on a mg/m<sup>2</sup> basis). The no effect level for juvenile neurobehavioral development in rats was 5 mg/kg/day (approximately 0.5 times the MRHD given to children on a mg/m<sup>2</sup> basis). The clinical significance of the long-term behavioral effects observed in rats is unknown.</paragraph>
                     </text>
                     <effectiveTime value="20250219"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_78b851e8-0700-4a4e-886b-585cc0b2e277">
                     <id root="2ff280fc-22ad-4aa0-9a2f-95f59b1805ae"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>Methylphenidate hydrochloride has not been studied in the geriatric population.</paragraph>
                     </text>
                     <effectiveTime value="20250219"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_826d2134-a6d9-4fc4-87a5-36eb6919a714">
               <id root="4e9bd9d4-e6f6-48db-b821-eb6ae1d182a2"/>
               <code code="42227-9" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG ABUSE AND DEPENDENCE SECTION"/>
               <title>9 DRUG ABUSE AND DEPENDENCE</title>
               <effectiveTime value="20250219"/>
               <component>
                  <section ID="LINK_800db125-b50f-4ee4-8806-c54c15c1c08d">
                     <id root="495dd0e1-bf59-4a9e-bdfd-4d46e3b7e3bd"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>9.1 Controlled
Substance</title>
                     <text>
                        <paragraph>Methylphenidate hydrochloride tablets contain methylphenidate hydrochloride, a Schedule II controlled substance.</paragraph>
                     </text>
                     <effectiveTime value="20250219"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_97dbb899-70dd-4de8-8619-a8e124f8ddee">
                     <id root="8928c392-6494-4af8-89c3-8692e2b9a6ea"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>9.2 Abuse</title>
                     <text>
                        <paragraph>Methylphenidate hydrochloride has a high potential for abuse and misuse which can lead to the development of a substance use disorder, including addiction <content styleCode="italics">[see <linkHtml href="#www.splportal.comLINK_c96ab80b-f758-4ed6-bd73-5c111c1410ad">Warnings and Precautions (5.1)</linkHtml>]</content>. Methylphenidate hydrochloride can be diverted for non-medical use into illicit channels or distribution.</paragraph>
                        <paragraph>Abuse is the intentional non-therapeutic use of a drug, even once, to achieve a desired psychological or physiological effect. Misuse is the intentional use, for therapeutic purposes, of a drug by an individual in a way other than prescribed by a health care provider or for whom it was not prescribed. Drug addiction is a cluster of behavioral, cognitive, and physiological phenomena that may include a strong desire to take the drug, difficulties in controlling drug use (e.g., continuing drug use despite harmful consequences, giving a higher priority to drug use than other activities and obligations), and possible tolerance or physical dependence.</paragraph>
                        <paragraph>Misuse and abuse of methylphenidate hydrochloride may cause increased heart rate, respiratory rate, or blood pressure; sweating; dilated pupils; hyperactivity; restlessness; insomnia; decreased appetite; loss of coordination; tremors; flushed skin; vomiting; and/or abdominal pain. Anxiety, psychosis, hostility, aggression, and suicidal or homicidal ideation have also been observed with CNS stimulants abuse and/or misuse. Misuse and abuse of CNS stimulants, including methylphenidate hydrochloride, can result in overdose and death <content styleCode="italics">[see <linkHtml href="#www.splportal.comLINK_85cd87d0-dfcc-4ec2-a4a5-99b1cd9fe877">Overdosage (10)</linkHtml>]</content>, and this risk is increased with higher doses or unapproved methods of administration, such as snorting or injection.</paragraph>
                     </text>
                     <effectiveTime value="20250219"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_5cd2698b-cc83-4cd9-8f9a-5139ddc4385d">
                     <id root="e9b4d720-26cd-4828-a061-eb3f1d39af5d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>9.3 Dependence</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Physical Dependence</content>
                        </paragraph>
                        <paragraph>Methylphenidate hydrochloride may produce physical dependence. Physical dependence is a state that develops as a result of physiological adaptation in response to repeated drug use, manifested by withdrawal signs and symptoms after abrupt discontinuation or a significant dose reduction of a drug.</paragraph>
                        <paragraph>Withdrawal signs and symptoms after abrupt discontinuation or dose reduction following prolonged use of CNS stimulants including methylphenidate hydrochloride include dysphoric mood; depression; fatigue; vivid, unpleasant dreams; insomnia or hypersomnia; increased appetite; and psychomotor retardation or agitation.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Tolerance</content>
                        </paragraph>
                        <paragraph>Methylphenidate hydrochloride may produce tolerance. Tolerance is a physiological state characterized by a reduced response to a drug after repeated administration (i.e., a higher dose of a drug is required to produce the same effect that was once obtained at a lower dose).</paragraph>
                     </text>
                     <effectiveTime value="20250219"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_85cd87d0-dfcc-4ec2-a4a5-99b1cd9fe877">
               <id root="1d18e3ea-34f7-4805-996a-076253457bb8"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <text>
                  <paragraph>
                     <content styleCode="underline">Clinical Effects of Overdose</content>
                  </paragraph>
                  <paragraph>Overdose of CNS stimulants is characterized by the following sympathomimetic effects:</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Cardiovascular effects including tachyarrhythmias, and hypertension or hypotension. Vasospasm, myocardial infarction, or aortic dissection may precipitate sudden cardiac death. Takotsubo cardiomyopathy may develop.</item>
                     <item>CNS effects including psychomotor agitation, confusion, and hallucinations. Serotonin syndrome, seizures, cerebral vascular accidents, and coma may occur.</item>
                     <item>Life-threatening hyperthermia (temperatures greater than 104°F) and rhabdomyolysis may develop.</item>
                  </list>
                  <paragraph>
                     <content styleCode="underline">Overdose Management</content>
                  </paragraph>
                  <paragraph>Consider the possibility of multiple drug ingestion. Because methylphenidate has a large volume of distribution and is rapidly metabolized, dialysis is not useful. Consider contacting the Poison Help line (1-800-222-1222) or a medical toxicologist for additional overdose management recommendations.</paragraph>
               </text>
               <effectiveTime value="20250219"/>
            </section>
         </component>
         <component>
            <section ID="LINK_33814d9e-a00c-4b00-9b9a-f701ddbf6f24">
               <id root="efd36a25-432b-4d4a-a78e-fe54da061794"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>Methylphenidate hydrochloride tablets, USP contains methylphenidate hydrochloride USP, a CNS stimulant. It is available as tablets of 5 mg, 10 mg and 20 mg strengths for oral administration.</paragraph>
                  <paragraph>Methylphenidate hydrochloride, USP is methyl α-phenyl-2-piperidineacetate hydrochloride, and its structural formula is:</paragraph>
                  <renderMultiMedia referencedObject="MM1"/>
                  <paragraph>Methylphenidate hydrochloride, USP is a white to off-white powder. Its solutions are acid to litmus. It is freely soluble in water and in methanol, soluble in alcohol, and slightly soluble in chloroform and in acetone. Its molecular weight is 269.77 g/mol.</paragraph>
                  <paragraph>Methylphenidate hydrochloride tablets, USP contain the following inactive ingredients: Lactose monohydrate, microcrystalline cellulose, stearic acid and FD&amp;C Yellow No. 6 Aluminum Lake.</paragraph>
               </text>
               <effectiveTime value="20250219"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>1</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="methylphenidate-hydrochloride-tablets-1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_c5042062-5c28-4c6f-9447-c988bbbfe723">
               <id root="4209c51e-78fa-4c11-9887-0a575880ec6d"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20250219"/>
               <component>
                  <section ID="LINK_b9159e0c-fb84-4e60-be8d-98f99a1e4c5d">
                     <id root="9edec238-3a5c-4a6f-bffe-7c1d29cc6f4d"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>Methylphenidate hydrochloride is a central nervous system (CNS) stimulant. The mode of therapeutic action in ADHD and narcolepsy is not known.</paragraph>
                     </text>
                     <effectiveTime value="20250219"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_a47b52c1-459d-40c0-8b43-ea5fd45aa4aa">
                     <id root="6079c8fb-743e-42be-8deb-0e6efcc01ab6"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <text>
                        <paragraph>Methylphenidate is a racemic mixture comprised of the <content styleCode="italics">d- </content>and <content styleCode="italics">l-threo </content>enantiomers. The <content styleCode="italics">d-threo </content>enantiomer is more pharmacologically active than the <content styleCode="italics">l-threo </content>enantiomer. Methylphenidate blocks the reuptake of norepinephrine and dopamine into the presynaptic neuron and increases the release of these monoamines into the extraneuronal space.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Cardiac Electrophysiology</content>
                        </paragraph>
                        <paragraph>A formal QT study has not been conducted in patients taking methylphenidate hydrochloride tablets.</paragraph>
                        <paragraph> The effect of dexmethylphenidate, the pharmacologically active <content styleCode="italics">d</content>-enantiomer of methylphenidate hydrochloride tablet, on the QT interval was evaluated in a double-blind, placebo- and open-label active (moxifloxacin)-controlled study following single doses of dexmethlyphenidate XR 40 mg (maximum recommended adult total daily dosage) in 75 healthy volunteers. Electrocardiograms (ECGs) were collected up to 12 hours postdose. Frederica’s method for heart rate correction was employed to derive the corrected QT interval (QTcF). The maximum mean prolongation of QTcF intervals was less than 5 ms, and the upper limit of the 90% confidence interval (CI) was below 10 ms for all time-matched comparisons versus placebo. This was below the threshold of clinical concern and there was no evident exposure response relationship.</paragraph>
                     </text>
                     <effectiveTime value="20250219"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_e8886aac-ab0f-4b04-a6a5-c7631e43e4c6">
                     <id root="e447c126-f8f1-47d8-9a1b-d915ac687fa2"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Absorption</content>
                        </paragraph>
                        <paragraph>The absolute bioavailability of methylphenidate is 22 ± 8% for the d-enantiomer and 5 ± 3% for the l-enantiomer. Peak plasma concentrations of approximately 4.3 ± 2.3 ng/mL were reached on an average of 2 hours after administration of 10 mg tablet. The time to peak rate in children was 1.9 hours (0.3 to 4.4 hours) for methylphenidate hydrochloride.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Effect of Food </content>
                        </paragraph>
                        <paragraph>Ingestion with food has no relevant effect on absorption of methylphenidate hydrochloride.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Distribution</content>
                        </paragraph>
                        <paragraph>Binding to plasma proteins is low (10% to 33%). The volume of distribution was 2.65 ± 1.11 L/kg for d-methylphenidate and 1.80 ± 0.91 L/kg for <content styleCode="italics">l</content>-methylphenidate.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Elimination</content>
                        </paragraph>
                        <paragraph>The systemic clearance is 0.40 ± 0.12 L/h/kg for d-methylphenidate and 0.73 ± 0.28 L/h/kg for <content styleCode="italics">l</content>-methylphenidate.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Metabolism</content>
                        </paragraph>
                        <paragraph>Methylphenidate is metabolized primarily by de-esterification to alpha-phenyl-piperidine acetic acid (ritalinic acid), which has little or no pharmacologic activity.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Excretion</content>
                        </paragraph>
                        <paragraph>After oral administration, 78% to 97% of the dose is excreted in the urine and 1% to 3% in feces in the form of metabolites within 48 to 96 hours. Most of the dose is excreted in the urine as alpha-phenyl-2-piperidine acetic acid (60% to 86%). </paragraph>
                        <paragraph>
                           <content styleCode="underline">Studies in Specific Populations</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Male and Female Patients</content>
                        </paragraph>
                        <paragraph>No gender differences in the pharmacokinetics of methylphenidate between healthy male and female adults are expected.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Racial or Ethnic Groups</content>
                        </paragraph>
                        <paragraph>There is insufficient experience with the use of methylphenidate hydrochloride tablets to detect ethnic variations in pharmacokinetics.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Patients with Renal Impairment</content>
                        </paragraph>
                        <paragraph>Methylphenidate hydrochloride tablets have not been studied in renally-impaired patients. Renal impairment is expected to have minimal effect on the pharmacokinetics of methylphenidate since less than 1% of a radiolabeled dose is excreted in the urine as unchanged compound, and the major metabolite (ritalinic acid), has little or no pharmacologic activity.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Patients with Hepatic Impairment</content>
                        </paragraph>
                        <paragraph>Methylphenidate hydrochloride tablets have not been studied in patients with hepatic impairment. Hepatic impairment is expected to have minimal effect on the pharmacokinetics of methylphenidate since it is metabolized primarily to ritalinic acid by nonmicrosomal hydrolytic esterases that are widely distributed throughout the body.</paragraph>
                     </text>
                     <effectiveTime value="20250219"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_f3f917db-9722-401d-bdf4-b2c4b19a849f">
               <id root="04c3276c-6671-4fc6-b4e0-0e50e61629ce"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20250219"/>
               <component>
                  <section ID="LINK_caa82b00-f125-47a9-a51e-76f360bde2c7">
                     <id root="5ad201d5-80ae-4a7e-bd3c-8f8444d54e06"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, and Impairment of
Fertility</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Carcinogenesis</content>
                        </paragraph>
                        <paragraph>In a lifetime carcinogenicity study carried out in B6C3F1 mice, methylphenidate caused an increase in hepatocellular adenomas, and in males only, an increase in hepatoblastomas at a daily dose of approximately 60 mg/kg/day. This dose is approximately 2 times the MRHD of 60 mg/day given to children on mg/m<sup>2</sup> basis. Hepatoblastoma is a relatively rare rodent malignant tumor type. There was no increase in total malignant hepatic tumors. The mouse strain used is sensitive to the development of hepatic tumors and the significance of these results to humans is unknown.</paragraph>
                        <paragraph>Methylphenidate did not cause any increase in tumors in a lifetime carcinogenicity study carried out in F344 rats; the highest dose used was approximately 45 mg/kg/day, which is approximately 4 times the MRHD (children) on a mg/m<sup>2</sup> basis.</paragraph>
                        <paragraph>In a 24-week carcinogenicity study in the transgenic mouse strain p53+/-, which is sensitive to genotoxic carcinogens, there was no evidence of carcinogenicity. Male and female mice were fed diets containing the same concentration of methylphenidate as in the lifetime carcinogenicity study; the high-dose groups were exposed to 60 mg/kg/day to 74 mg/kg/day of methylphenidate.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Mutagenesis</content>
                        </paragraph>
                        <paragraph>Methylphenidate was not mutagenic in the <content styleCode="italics">in vitro </content>Ames reverse mutation assay, in the <content styleCode="italics">in vitro </content>mouse lymphoma cell forward mutation assay, or in the <content styleCode="italics">in vitro </content>chromosomal aberration assay using human lymphocytes. Sister chromatid exchanges and chromosome aberrations were increased, indicative of a weak clastogenic response, in an <content styleCode="italics">in vitro</content> assay in cultured Chinese Hamster Ovary (CHO) cells. Methylphenidate was negative <content styleCode="italics">in vivo </content>in males and females in the mouse bone marrow micronucleus assay.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Impairment of Fertility</content>
                        </paragraph>
                        <paragraph>No human data on the effect of methylphenidate on fertility are available. Methylphenidate did not impair fertility in male or female mice that were fed diets containing the drug in an 18-week continuous breeding study. The study was conducted at doses up to 160 mg/kg/day, approximately 10 times the MRHD of 60 mg/day given to adolescents on a mg/m<sup>2</sup> basis.</paragraph>
                     </text>
                     <effectiveTime value="20250219"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_082b16e2-44bd-411f-a64a-d105bdafaff2">
               <id root="f1fac82f-27ef-4ff4-bc4b-787830947014"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph>Methylphenidate hydrochloride tablets USP, <content styleCode="bold">5 mg</content> are supplied as light orange to orange, round compressed tablets, debossed <content styleCode="bold">cor </content>on one side and <content styleCode="bold">237 </content>on the other side.</paragraph>
                  <paragraph>They are available as follows:</paragraph>
                  <paragraph>Bottles of 100:            NDC 0115-1800-01</paragraph>
                  <paragraph>Methylphenidate hydrochloride tablets USP, <content styleCode="bold">10 mg</content> are supplied as light orange to orange, round compressed tablets, debossed <content styleCode="bold">cor </content>above <content styleCode="bold">bisect </content>and <content styleCode="bold">238 </content>below the bisect on one side and plain on the other side.</paragraph>
                  <paragraph>They are available as follows:</paragraph>
                  <paragraph>Bottles of 100:            NDC 0115-1801-01</paragraph>
                  <paragraph>Methylphenidate hydrochloride tablets USP, <content styleCode="bold">20 mg</content> are supplied as light orange to orange, round compressed tablets, debossed <content styleCode="bold">cor </content>over <content styleCode="bold">239 </content>on one side and <content styleCode="bold">bisect </content>on the other side.</paragraph>
                  <paragraph>They are available as follows:</paragraph>
                  <paragraph>Bottles of 100:            NDC 0115-1802-01</paragraph>
                  <paragraph>Store at 20° to 25°C (68° to 77°F); excursions permitted between 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].</paragraph>
                  <paragraph>Protect from light.</paragraph>
                  <paragraph>Dispense in tight, light-resistant container (USP).</paragraph>
               </text>
               <effectiveTime value="20250219"/>
            </section>
         </component>
         <component>
            <section ID="LINK_7c856679-7176-4538-b26d-22c9318fbdc5">
               <id root="0e3d3821-8721-4875-b054-7069745167ca"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>Advise the patient to read the FDA-approved patient labeling <linkHtml href="#www.splportal.comLINK_ac49b7a3-118b-4dea-a87e-de0e6e7751a6">(Medication Guide)</linkHtml>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Abuse, Misuse, and Addiction</content>
                  </paragraph>
                  <paragraph>Educate patients and their families about the risks of abuse, misuse, and addiction of methylphenidate hydrochloride, which can lead to overdose and death, and proper disposal of any unused drug <content styleCode="italics">[see <linkHtml href="#www.splportal.comLINK_c96ab80b-f758-4ed6-bd73-5c111c1410ad">Warnings and Precautions (5.1)</linkHtml>, <content styleCode="italics">
                           <linkHtml href="#www.splportal.comLINK_97dbb899-70dd-4de8-8619-a8e124f8ddee">Drug Abuse and Dependence</linkHtml>
                        </content>
                        <content styleCode="italics">
                           <linkHtml href="#www.splportal.comLINK_97dbb899-70dd-4de8-8619-a8e124f8ddee"> (9.2)</linkHtml>
                        </content>, <linkHtml href="#www.splportal.comLINK_85cd87d0-dfcc-4ec2-a4a5-99b1cd9fe877">Overdosage (10)</linkHtml>]</content>. Advise patients to store methylphenidate hydrochloride in a safe place, preferably locked, and instruct patients to not give methylphenidate hydrochloride to anyone else.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Risks to Patients with Serious Cardiac Disease</content>
                  </paragraph>
                  <paragraph>Advise patients that there are potential risks to patient with serious cardiac disease, including sudden death, with methylphenidate hydrochloride use. Instruct patients to contact a healthcare provider immediately if they develop symptoms, such as exertional chest pain, unexplained syncope, or other symptoms suggestive of cardiac disease <content styleCode="italics">[see <linkHtml href="#www.splportal.comLINK_1f9a2b47-8373-4eb2-a622-cd2bb8edf511">Warnings and Precautions (5.2)</linkHtml>].</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Increased Blood Pressure and Heart Rate</content>
                  </paragraph>
                  <paragraph>Instruct patients that methylphenidate hydrochloride can cause elevations of their blood pressure and pulse rate <content styleCode="italics">[see <linkHtml href="#www.splportal.comLINK_ee01e211-af26-45f2-b0b3-029dced0f0bb">Warnings and Precautions (5.3)</linkHtml>]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Psychiatric Adverse Reactions</content>
                  </paragraph>
                  <paragraph>Advise patients that methylphenidate hydrochloride, at recommended doses, can cause psychotic or manic symptoms, even in patients without prior history of psychotic symptoms or mania <content styleCode="italics">[see <linkHtml href="#www.splportal.comLINK_59e56115-b452-4512-ae37-4f958ebb7f0a">Warnings and Precautions (5.4)</linkHtml>].</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Priapism</content>
                  </paragraph>
                  <paragraph>Advise patients of the possibility of painful or prolonged penile erections (priapism). Instruct them to seek immediate medical attention in the event of priapism <content styleCode="italics">[see <linkHtml href="#www.splportal.comLINK_56c5a188-e205-4c08-bbf4-37ac98ad36d1">Warnings and Precautions (5.5)</linkHtml>]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Circulation Problems in Fingers and Toes [Peripheral Vasculopathy, Including Raynaud’s Phenomenon]</content>
                  </paragraph>
                  <paragraph>Instruct patients about the risk of peripheral vasculopathy, including Raynaud’s Phenomenon, and associated signs and symptoms: fingers or toes may feel numb, cool, painful, and/or may change color from pale, to blue, to red. Instruct patients to report to their physician any new numbness, pain, skin color change, or sensitivity to temperature in fingers or toes.</paragraph>
                  <paragraph>Instruct patients to call their physician immediately with any signs of unexplained wounds appearing on fingers or toes while taking methylphenidate hydrochloride. Further clinical evaluation (e.g., rheumatology referral) may be appropriate for certain patients <content styleCode="italics">[see <linkHtml href="#www.splportal.comLINK_28a40a99-6c79-467f-8155-8d573f38d88e">Warnings and Precautions (5.6)</linkHtml>]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Long-Term Suppression of Growth in Pediatric Patients</content>
                  </paragraph>
                  <paragraph>Advise patients that methylphenidate hydrochloride may cause slowing of growth and weight loss <content styleCode="italics">[see <linkHtml href="#www.splportal.comLINK_90c6eac8-4d1f-4927-9954-5e8dcb549a15">Warnings and Precautions (5.7)</linkHtml>].</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Increased Intraocular Pressure (IOP) and Glaucoma</content>
                  </paragraph>
                  <paragraph>Advise patients that IOP and glaucoma may occur during treatment with methylphenidate hydrochloride<content styleCode="italics"> [see <linkHtml href="#www.splportal.comLINK_e47d8db2-1651-4114-836e-980b11f1eda3">Warnings and Precautions (5.9)</linkHtml>]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Motor and Verbal Tics, and Worsening of Tourette’s Syndrome</content>
                  </paragraph>
                  <paragraph>Advise patients that motor and verbal tics and worsening of Tourette’s Syndrome may occur during treatment with methylphenidate hydrochloride. Instruct patients to notify their healthcare provider if emergence of new tics or worsening of tics or Tourette’s syndrome occurs <content styleCode="italics">[see <linkHtml href="#www.splportal.comLINK_f29a082f-65f3-4d24-a9b5-5051004f0f18">Warnings and Precautions (5.10)</linkHtml>]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Pregnancy Registry</content>
                  </paragraph>
                  <paragraph>Advise patients that there is a pregnancy exposure registry that monitors pregnancy outcomes in patients exposed to ADHD medications, including methylphenidate hydrochloride, during pregnancy <content styleCode="italics">[see <linkHtml href="#www.splportal.comLINK_a5cc5456-2fc5-4095-b41b-6009cc71135a">Use in Specific Populations (8.1)</linkHtml>]</content>.</paragraph>
                  <paragraph>Distributed by:<br/>
                     <content styleCode="bold">Amneal Pharmaceuticals LLC<br/>
                     </content>Bridgewater, NJ 08807</paragraph>
                  <paragraph>Rev. 02-2025-05</paragraph>
                  <paragraph>Dispense with Medication Guide available at:<br/>
documents.amneal.com/mg/methylphenidate-hcl-tablets.pdf</paragraph>
               </text>
               <effectiveTime value="20250219"/>
            </section>
         </component>
         <component>
            <section ID="LINK_ac49b7a3-118b-4dea-a87e-de0e6e7751a6">
               <id root="d5297acb-a31f-4db6-ba81-ebbc023735c3"/>
               <code code="42231-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL MEDGUIDE SECTION"/>
               <title>MEDICATION GUIDE</title>
               <text>
                  <table>
                     <col/>
                     <tbody>
                        <tr>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Methylphenidate Hydrochloride<br/>
                                 </content>
                                 <content styleCode="bold">(meth" il fen' i date hye" droe klor' ide)<br/>
                                 </content>
                                 <content styleCode="bold">
                                    <content styleCode="bold">Tablets, for oral use, CII</content>
                                 </content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">What is the most important information I should know about methylphenidate hydrochloride tablets?</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Methylphenidate hydrochloride tablets may cause serious side effects, including:</content>
                              </paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">Abuse, misuse, and addiction.</content> Methylphenidate hydrochloride tablets have a high chance for abuse and misuse and may lead to substance use problems, including addiction. Misuse and abuse of methylphenidate hydrochloride tablets, other methylphenidate containing medicines, and amphetamine containing medicines, can lead to overdose and death. The risk of overdose and death is increased with higher doses of methylphenidate hydrochloride tablets or when it is used in ways that are not approved, such as snorting or injection.</item>
                              </list>
                              <list listType="unordered" styleCode="Circle">
                                 <item>Your healthcare provider should check you or your child’s risk for abuse, misuse, and addiction before starting treatment with methylphenidate hydrochloride tablets and will monitor you or your child during treatment.</item>
                                 <item>Methylphenidate hydrochloride tablets may lead to physical dependence after prolonged use, even if taken as directed by your healthcare provider.</item>
                                 <item>Do not give methylphenidate hydrochloride tablets to anyone else. See <content styleCode="bold">“What is </content>
                                    <content styleCode="bold">methylphenidate hydrochloride tablets?”</content> for more information.</item>
                                 <item>Keep methylphenidate hydrochloride tablets in a safe place and properly dispose of any unused medicine. See <content styleCode="bold">“How should I store </content>
                                    <content styleCode="bold">methylphenidate hydrochloride tablets?”</content> for more information.</item>
                                 <item>Tell your healthcare provider if you or your child have ever abused or been dependent on alcohol, prescription medicines, or street drugs.
                <list listType="unordered" styleCode="Disc">
                                       <item>
                                          <content styleCode="bold">Risks for people with serious heart disease.</content> Sudden death has happened in people who have heart defects or other serious heart disease.</item>
                                    </list>
                                 </item>
                              </list>
                              <paragraph>Your healthcare provider should check you or your child carefully for heart problems before starting methylphenidate hydrochloride tablets.</paragraph>
                              <paragraph>Tell your healthcare provider if you or your child have any heart problems, heart disease, or heart defects.</paragraph>
                              <paragraph>
                                 <content styleCode="bold">Call your healthcare provider or go to the nearest hospital emergency room right away if you or your child has any signs of heart problems, such as chest pain, shortness of breath, or fainting while taking methylphenidate hydrochloride tablets.</content>
                              </paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">Increased blood pressure and heart rate.</content>
                                    <paragraph>Your healthcare provider should check you or your child’s blood pressure and heart rate regularly during treatment with methylphenidate hydrochloride tablets.</paragraph>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Mental (psychiatric) problems:</content>
                                 </item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">All Patients</content>
                              </paragraph>
                              <list listType="unordered" styleCode="Circle">
                                 <item>new or worse behavior and thought problems</item>
                                 <item>new or worse bipolar illness</item>
                                 <item>new psychotic symptoms (such as hearing voices, believing things that are not true, are suspicious) or new manic symptoms</item>
                              </list>
                              <paragraph>Tell your healthcare provider about any mental problems you or your child have, or about a family history of suicide, bipolar illness, or depression.</paragraph>
                              <paragraph>
                                 <content styleCode="bold">Call your healthcare provider right away if you or your child have any new or worsening mental symptoms or problems while taking methylphenidate hydrochloride tablets, especially seeing or hearing things that are not real, believing things that are not real, or are suspicious.</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">What are methylphenidate hydrochloride tablets?</content>
                              </paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Methylphenidate hydrochloride tablets are a central nervous system (CNS) stimulant prescription medicine. <content styleCode="bold">It is used for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). </content>Methylphenidate hydrochloride tablets may help increase attention and decrease impulsiveness and hyperactivity in patients with ADHD.</item>
                                 <item>Methylphenidate hydrochloride tablets should be used as a part of a total treatment program for ADHD that may include counseling or other therapies.</item>
                                 <item>Methylphenidate hydrochloride tablets are also used in the treatment of a sleep disorder called narcolepsy.</item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">It is not known if methylphenidate hydrochloride tablets are safe and effective in children under 6 years of age.</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Methylphenidate hydrochloride tablets are a federally controlled substance (CII) because it contains methylphenidate that can be a target for people who abuse prescription medicines or street drugs.</content> Keep methylphenidate hydrochloride tablets in a safe place to protect it from theft. Never give your methylphenidate hydrochloride tablets to anyone else, because it may cause death or harm them. Selling or giving away methylphenidate hydrochloride tablets may harm others and is against the law.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Who should not take methylphenidate hydrochloride tablets?</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Methylphenidate hydrochloride tablets should not be taken if you or your child:</content>
                              </paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>are allergic to methylphenidate hydrochloride, or any of the ingredients in methylphenidate hydrochloride tablets. See the end of this Medication Guide for a complete list of ingredients in methylphenidate hydrochloride tablets.</item>
                                 <item>are taking or have taken within the past 14 days an anti-depression medicine called a monoamine oxidase inhibitor (MAOI).</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Methylphenidate hydrochloride tablets may not be right for you or your child. Before starting methylphenidate hydrochloride tablets tell your or your child’s healthcare provider about all health conditions (or a family history of), including:</content>
                              </paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>heart problems, heart disease, heart defects, or high blood pressure</item>
                                 <item>mental problems, including psychosis, mania, bipolar illness, or depression</item>
                                 <item>circulation problems in fingers or toes</item>
                              </list>
                              <list listType="unordered" styleCode="Disc">
                                 <item>have eye problems, including increased pressure in your eye, glaucoma, or problems with your close-up vision (farsightedness) </item>
                                 <item>have or had repeated movements or sounds (tics) or Tourette’s syndrome, or have a family history of tics or Tourette’s syndrome.</item>
                              </list>
                              <list listType="unordered" styleCode="Disc">
                                 <item>if you are pregnant or plan to become pregnant. It is not known if methylphenidate hydrochloride tablets will harm your unborn baby. </item>
                              </list>
                              <list listType="unordered" styleCode="Circle">
                                 <item>There is a pregnancy registry for females who are exposed to ADHD medications, including methylphenidate hydrochloride tablets, during pregnancy. The purpose of the registry is to collect information about the health of females exposed to methylphenidate hydrochloride tablets and their baby. If you or your child becomes pregnant during treatment with methylphenidate hydrochloride tablets, talk to your healthcare provider about registering with the National Pregnancy Registry of ADHD Medications at 1-866-961-2388 or visit online at https://womensmentalhealth.org/adhd-medications/.
                <list listType="unordered" styleCode="Disc">
                                       <item>if you are breastfeeding or plan to breastfeed. Methylphenidate hydrochloride passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby during treatment with methylphenidate hydrochloride.</item>
                                    </list>
                                    <paragraph>
                                       <content styleCode="bold">Tell your healthcare provider about all of the medicines that you or your child takes, including prescription and over-the-counter medicines, vitamins, and herbal supplements. </content>Methylphenidate hydrochloride tablets and some medicines may interact with each other and cause serious side effects. Sometimes the doses of other medicines will need to be adjusted while taking methylphenidate hydrochloride tablets. </paragraph>
                                    <paragraph>Your healthcare provider will decide whether methylphenidate hydrochloride tablets can be taken with other medicines.</paragraph>
                                    <paragraph>
                                       <content styleCode="bold">Especially tell your healthcare provider if you or your child takes:</content>
                                    </paragraph>
                                    <list listType="unordered" styleCode="Disc">
                                       <item>anti-depression medicines, including monoamine oxidase inhibitors (MAOIs)</item>
                                       <item>blood pressure medicines (anti-hypertensive)</item>
                                    </list>
                                    <paragraph>Know the medicines that you or your child takes. Keep a list of your medicines with you to show your healthcare provider and pharmacist.</paragraph>
                                    <list listType="unordered" styleCode="Disc">
                                       <item>You should not take methylphenidate hydrochloride tablets on the day of your operation if a certain type of anesthetic is used. This is because there is a chance of a sudden rise in blood pressure and heart rate during the operation.</item>
                                    </list>
                                 </item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">Do not start any new medicine while taking methylphenidate hydrochloride tablets without talking to your healthcare provider first.</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">How should methylphenidate hydrochloride tablets be taken?</content>
                              </paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Take methylphenidate hydrochloride tablets exactly as prescribed<content styleCode="bold">. </content>Your healthcare provider may adjust the dose until it is right for you or your child.</item>
                                 <item>Methylphenidate hydrochloride tablet is usually taken 2 to 3 times a day.</item>
                                 <item>Take methylphenidate hydrochloride tablet 30 to 45 minutes before a meal.</item>
                                 <item>Your healthcare provider may do regular checks of the blood, heart, and blood pressure while taking methylphenidate hydrochloride tablets.</item>
                                 <item>Children should have their height and weight checked often while taking methylphenidate hydrochloride tablets. </item>
                              </list>
                              <paragraph>If you or your child take too many methylphenidate hydrochloride tablets, call your healthcare provider or Poison Help line at 1-800-222-1222 or go to the nearest hospital emergency room right away.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">What are the possible side effects of methylphenidate hydrochloride tablets?</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Methylphenidate hydrochloride tablets may cause serious side effects, including:</content>
                              </paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>see <content styleCode="bold">“What is the most important information I should know about methylphenidate hydrochloride tablets?” </content>for information on reported heart and mental problems.</item>
                                 <item>
                                    <content styleCode="bold">painful and prolonged erections (priapism) </content>have occurred with methylphenidate. If you or your child develops priapism, seek medical help right away. Because of the potential for lasting damage, priapism should be evaluated by a healthcare provider immediately.</item>
                                 <item>
                                    <content styleCode="bold">circulation problems in fingers and toes </content>(peripheral vasculopathy, including Raynaud’s phenomenon):</item>
                              </list>
                              <list listType="unordered" styleCode="Circle">
                                 <item>fingers or toes may feel numb, cool, painful</item>
                                 <item>fingers or toes may change color from pale, to blue, to red
                <paragraph>Tell your healthcare provider if you or your child have, numbness, pain, skin color change, or sensitivity to temperature in the fingers or toes.</paragraph>
                                    <paragraph>
                                       <content styleCode="bold">Call your healthcare provider right away if you have or your child has any signs of unexplained wounds appearing on fingers or toes while taking methylphenidate hydrochloride tablets.</content>
                                    </paragraph>
                                    <list listType="unordered" styleCode="Disc">
                                       <item>
                                          <content styleCode="bold">Slowing of growth (height and weight) in children. </content>Children should have their height and weight checked often during treatment with methylphenidate hydrochloride tablets. Methylphenidate hydrochloride tablets treatment may be stopped if your child is not growing or gaining weight.</item>
                                    </list>
                                 </item>
                              </list>
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">Eye problems (increased pressure in the eye and glaucoma).</content> Call your healthcare provider right away if you or your child develop changes in your vision or eye pain, swelling, or redness.</item>
                                 <item>
                                    <content styleCode="bold">New or worsening tics or worsening Tourette’s syndrome.</content> Tell your healthcare provider if you or your child get any new or worsening tics or worsening Tourette’s syndrome during treatment with methylphenidate hydrochloride tablets.</item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">Common side effects include:</content>
                              </paragraph>
                              <list listType="unordered" styleCode="Disk">
                                 <item>fast heart beat</item>
                                 <item>abnormal heartbeat (palpitations)</item>
                                 <item>headache</item>
                                 <item>trouble sleeping</item>
                                 <item>nervousness</item>
                                 <item>sweating a lot</item>
                                 <item>decreased appetite</item>
                                 <item>dry mouth</item>
                                 <item>nausea</item>
                                 <item>stomach pain</item>
                              </list>
                              <paragraph>Call your doctor for medical advice about side effects. <content styleCode="bold">You may report side effects to FDA at 1-800-FDA-1088.</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">How should I store methylphenidate hydrochloride tablets?</content>
                              </paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Store methylphenidate hydrochloride tablets in a safe place and in a tightly closed container at room temperature between 20° to 25°C (68° to 77°F); excursions permitted between 15° to 30°C (59° to 86°F).</item>
                                 <item>Protect from light.</item>
                                 <item>Dispose of remaining, unused, or expired methylphenidate hydrochloride tablets by a medicine take-back program at a U.S. Drug Enforcement Administration (DEA) authorized collection site. If no take-back program or DEA authorized collector is available, mix methylphenidate hydrochloride tablets with an undesirable, nontoxic substance such as dirt, cat litter, or used coffee grounds to make it less appealing to children and pets. Place the mixture in a container, such as a sealed plastic bag and throw away methylphenidate hydrochloride tablets in the household trash. Visit www.fda.gov/drugdisposal for additional information on disposal of unused medicines.</item>
                                 <item>
                                    <content styleCode="bold">Keep methylphenidate hydrochloride tablets </content>
                                    <content styleCode="bold">and all medicines out of the reach of children.</content>
                                 </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">General information about the safe and effective use of methylphenidate hydrochloride tablets.</content>
                              </paragraph>
                              <paragraph>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. You can ask your pharmacist or healthcare provider for information about methylphenidate hydrochloride tablets that is written for healthcare professionals. Do not use methylphenidate hydrochloride tablets for a condition for which it was not prescribed. Do not give methylphenidate hydrochloride tablets to other people, even if they have the same symptoms that you have. It may harm them and it is against the law.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">What are the ingredients in </content>
                                 <content styleCode="bold">methylphenidate hydrochloride tablets</content>
                                 <content styleCode="bold">?</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Active ingredient: </content>methylphenidate hydrochloride, USP</paragraph>
                              <paragraph>
                                 <content styleCode="bold">Inactive ingredients: </content>Lactose monohydrate, microcrystalline cellulose, stearic acid and FD&amp;C Yellow No. 6 Aluminum Lake</paragraph>
                              <paragraph>For more information call, 1-877-835-5472.</paragraph>
                              <paragraph>This Medication Guide has been approved by the U.S. Food and Drug Administration.</paragraph>
                              <paragraph>Distributed by:<br/>
                                 <content styleCode="bold">Amneal Pharmaceuticals LLC<br/>
                                 </content>Bridgewater, NJ 08807</paragraph>
                              <paragraph>  Rev. 11-2023-04</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td>
                              <paragraph>Dispense with Medication Guide available at:<br/>
            documents.amneal.com/mg/methylphenidate-hcl-tablets.pdf</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20250219"/>
            </section>
         </component>
         <component>
            <section ID="LINK_387cc7b8-77cb-4fcc-8f94-b4997ccf5b3f">
               <id root="81d9e0b2-8978-4ad6-b996-27624481e829"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL 5 mg Bottle Label</title>
               <text>
                  <paragraph>NDC 0115-1800-01</paragraph>
                  <paragraph>Methylphenidate Hydrochloride Tablets USP, 5 mg</paragraph>
                  <paragraph>Rx only</paragraph>
                  <paragraph>Amneal Pharmaceuticals LLC</paragraph>
                  <renderMultiMedia referencedObject="MM2"/>
               </text>
               <effectiveTime value="20250219"/>
               <component>
                  <observationMedia ID="MM2">
                     <text>5 mg</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="methylphenidate-hydrochloride-tablets-2.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_47cee185-0a6e-4311-961a-2e4e2b6d87c6">
               <id root="bb4ca540-f794-4e38-8a1b-e08cf4a1c8b2"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL 10 mg Bottle Label</title>
               <text>
                  <paragraph>NDC 0115-1801-01</paragraph>
                  <paragraph>Methylphenidate Hydrochloride Tablets USP, 10 mg</paragraph>
                  <paragraph>Rx only</paragraph>
                  <paragraph>Amneal Pharmaceuticals LLC</paragraph>
                  <renderMultiMedia referencedObject="MM3"/>
               </text>
               <effectiveTime value="20250219"/>
               <component>
                  <observationMedia ID="MM3">
                     <text>10 mg</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="methylphenidate-hydrochloride-tablets-3.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_5c09ffa1-ed19-4096-a00f-046e0ae6d17d">
               <id root="3516d327-2ecf-428e-84ad-0499671b0b6c"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL 20 mg Bottle Label</title>
               <text>
                  <paragraph>NDC 0115-1802-01</paragraph>
                  <paragraph>Methylphenidate Hydrochloride Tablets USP, 20 mg</paragraph>
                  <paragraph>Rx only</paragraph>
                  <paragraph>Amneal Pharmaceuticals LLC</paragraph>
                  <renderMultiMedia referencedObject="MM4"/>
               </text>
               <effectiveTime value="20250219"/>
               <component>
                  <observationMedia ID="MM4">
                     <text>20 mg</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="methylphenidate-hydrochloride-tablets-4.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>